Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. Ruggeri B, et al. Among authors: pili r. Cancer Res. 2003 Sep 15;63(18):5978-91. Cancer Res. 2003. PMID: 14522925
Modified synthesis and antiangiogenic activity of linomide.
Khan SR, Mhaka A, Pili R, Isaacs JT. Khan SR, et al. Among authors: pili r. Bioorg Med Chem Lett. 2001 Feb 26;11(4):451-2. doi: 10.1016/s0960-894x(00)00699-5. Bioorg Med Chem Lett. 2001. PMID: 11229745
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Collins C, et al. Among authors: pili r. Cancer Biol Ther. 2007 Sep;6(9):1360-7. doi: 10.4161/cbt.6.9.4541. Epub 2007 Jun 5. Cancer Biol Ther. 2007. PMID: 17786033 Free PMC article.
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R. Adelaiye-Ogala R, et al. Among authors: pili r. Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4. Cancer Res. 2017. PMID: 28978636 Free PMC article.
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. Pili R, et al. Clin Genitourin Cancer. 2013 Dec;11(4):477-83. doi: 10.1016/j.clgc.2013.05.005. Epub 2013 Jul 26. Clin Genitourin Cancer. 2013. PMID: 23891158 Free PMC article. Clinical Trial.
235 results